Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Generic Drug User Fees Would Fund Faster ANDA Approvals Under FDA Budget

This article was originally published in The Pink Sheet Daily

Executive Summary

Agency’s $2.1 billion FY ’08 budget request also asks for more money for drug safety surveillance and assessment.

You may also be interested in...



FDA To Request Authority To Approve Follow-On Biologics

Agency again seeks user fees to pay for review of generic drug applications and direct-to-consumer TV ads; proposes $984 million budget for human drugs and biologics.

FDA To Request Authority To Approve Follow-On Biologics

Agency again seeks user fees to pay for review of generic drug applications and direct-to-consumer TV ads; proposes $984 million budget for human drugs and biologics.

Pilot Program Will Review First-Year Safety Data for Several NMEs

FDA outlines organizational steps and safety monitoring initiatives in response to IoM report on improving drug safety.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS065696

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel